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Abstract: Until recently, most research efforts aimed at developing anti-cancer tools were focusing on small molecules. 
Alternative compounds are now being increasingly assessed for their potential anti-cancer properties, including peptides 
and their derivatives. One earlier limitation to the use of peptides was their limited capacity to cross membranes but this 
limitation was alleviated with the characterization of cell-permeable sequences. Additionally, means are designed to target 
peptides to malignant cells. Most anti-cancer peptidic compounds induce apoptosis of tumor cells by modulating the activ-
ity of Bcl-2 family members that control the release of death factors from the mitochondria or by inhibiting negative regu-
lators of caspases, the proteases that mediate the apoptotic response in cells. Some of these peptides have been shown to 
inhibit the growth of tumors in mouse models. Hopefully, pro-apoptotic anti-tumor peptides will soon be tested for their 
efficacy in patients with cancers. 
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INTRODUCTION 
 In industrialized countries in general and in North Amer-
ica in particular, cancer is the second most important cause 
of death after heart diseases [1]. Although an important de-
crease was recorded in cancer death rates between 1990 and 
2005 (19.2 % for men and 11.4 % for women) in the United 
States, there are still about 1.5 million new cases of cancer 
estimated to occur in this country each year [1]. There is the 
need therefore to develop more efficient and selective cures 
to fight cancer. This will necessitate a further increase in our 
understanding of the mechanisms of cancer progression and 
the translation of this knowledge into the development of 
more efficient and specific anti-cancer drugs. 
 The characteristic features of a cancer cell have been 
classified by Hanahan and Weinberg into six categories: self-
sufficiency in growth factor, as well as insensitivity to anti-
growth signals, limitless replicative potential, capacity to 
metastasize and to sustain angiogenesis, and resistance to 
apoptosis [2]. A switch to aerobic glycolysis (the Warburg 
effect) is also recognized as the seventh hallmark by some 
[3-5]. All of these characteristic features of tumor cells can 
potentially represent targets for the development of anti-
cancer drugs. In terms of ultimate efficiency, induction of 
apoptosis in tumor cells might represent the ideal anti-tumor 
therapy as no problematic cells are left behind. 
 A perfect anti-cancer drug has to kill cancer cells specifi-
cally, sparing non-transformed cells. Fortunately, the meta-
bolic and cellular changes induced in tumor cells can be tar-
geted to provoke their demise. Strategies exploring the pos-
sibilities to restore an appropriate apoptotic response in can-
cer cells, or even better, to tip the balance in favor of pro-
apoptotic signals in these cells, are of great clinical interest. 
In this context, the use of therapeutic peptides as an alterna- 
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tive to small molecule drugs has become an increasingly 
promising strategy to induce cancer cell apoptosis in a spe-
cific and targeted manner. Peptides are of low molecular 
weight and generally display low toxicity and high bioavail-
ability. In addition, by fusing them to cell-penetrating moie-
ties, therapeutic peptides can display improved targetable 
and deliverable properties. Finally, they can be produced 
easily and at low cost. All these advantages have made the 
anti-cancer peptide research field very active lately as re-
ported in a number of interesting recent reviews [6-12]. 
 The present review will focus on therapeutic anti-cancer 
peptides targeting the apoptosis signaling pathway. There 
will be a brief description of the molecular mechanisms con-
trolling apoptosis, followed by a short section on recent im-
provements in peptide cell delivery. The main part of the 
review will however be devoted to the discussion of specific 
anti-tumor therapeutic peptides (the characteristics of which 
are described in Table 1). Work performed with protein se-
quences that have anti-cancer properties but that do not in-
volve synthetic peptides (e.g. ADD70 derived from AIF 
[13]) will not be touched upon here. 
Apoptosis 
 Apoptosis, or programmed cell death, is a physiological 
cell suicide program that is essential for the development and 
maintenance of healthy tissues [14]. Apoptosis is generally 
impaired during carcinogenesis, thereby preventing damaged 
cells to die [15,16]. However, it has to be noted that it is ac-
tually the balance between the rate of proliferation and the 
rate of death that determines tumor growth. There are cases 
of cancers displaying an increased apoptosis rate but where 
the population of cancer cells still increases due to over-
whelming proliferation [17]. Nevertheless, as defect in apop-
tosis often plays a major role in cancer generation, rescuing 
and inducing apoptosis to get rid of these potential dangerous 
cells arose as an attractive anti-cancer approach [16]. 
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Table 1. Characteristics of Pro-Apoptotic Peptides. This Table Displays the Nature and some of the Properties of the Peptides Described 
in this Review 






(Without CPP and CST) 
Reference(s) 
Ant-BH3 (Ant-Bak) Bak Pen  N/A No MGQVGRQLAIIGDDINRRY [65,71] 
R8-Bak Bak poly-Arg  N/A No MGQVGRQLAIIGDDINRRY [71] 
LHRH-BH3 Bak  LHRH Yes No MGQVGRQLAIIGDDINRRY [66] 
None given Bax  N/A No KLSECLKRIGDELDS [73-76] 
Ant-Bax Bax Pen  N/A No STKKLSECLKRIGDELDSNM [71,77] 
R8-Bax Bax poly-Arg  N/A No STKKLSECLKRIGDELDSNM [71,77] 




TAT-DV3-BH3 PUMA TAT DV3 Yes Yes LRRMADDLN [86] 








ANTBH3BAD Bad Pen  No No NLWAAQRYGRELRRMSDEFVD [97] 
Ant-Bad Bad Pen  No No NLWAAQRYGRELRRMSDEFVD [71,77] 
R8-Bad Bad poly-Arg  No No NLWAAQRYGRELRRMSDEFVD [71,77] 
SAHBA Bid   N/A Yes EDIIRNIARHLA*VGD*NLDRSIW [102] 
TAT-Bim Bim TAT  N/A Yes EIWIAQELRRIGDEFNAYYAR [106] 
peptide 2 IP3R  N/A No NVYTEIKCNSLLPLDDIVRV [111] 
None given Smac TAT  Yes Yes AVPIAQK [117] 







Variation of AVPI [118-121] 
None given Smac  N/A No AKPF dimer [123] 
None given Smac  N/A No AVP*IAQKSE [126] 
Shepherdin Survivin Pen  Yes Yes KHSSGCAFL [130] 
RI-TATp53C' p53 TAT DV3 Yes Yes KKHRSTSQGKKSKLHSSHARSG [138] 
Abbreviations not Mentioned in the Text: CST, Cancer-Specific Targeting; DV3, DV3 Domain of the CXC Chemokine Receptor-4; LHRH, Luteinizing Hormone Releasing Hor-
mone; Pen, Penetratin; N/A, not Analyzed. Asterisks Denote chemically Modified Amino-Acids. 
 Apoptosis is well characterized biochemically and mor-
phologically [14]. Cells undergoing apoptosis shrink, cleave 
their DNA, fragment their nucleus and organelles, and are 
partitioned into apoptotic bodies, ensuring their efficient 
elimination by professional phagocytes or neighboring cells 
[18-21]. All the characteristic features of apoptosis are in-
duced following the cleavage of substrates of proteases of 
the caspase family [14]. Caspases involved in apoptosis be-
long to either the upstream initiator caspases or the down-
stream effector caspases [22]. The effector caspases, 
caspase-3, -6, and -7, are activated by cleavage mediated by 
the initiator caspases (-8, -9, and -10). Whether caspase-2 is 
an upstream downstream caspase is still debated [23]. There 
are two main cellular pathways involved in caspase activa-
tion (Fig. 1). The intrinsic pathway involves the release of 
cytochrome-c from mitochondria, leading to formation of a 
multi-protein platform called the apoptosome that results in 
the activation of caspase-9. The apoptosome is formed when 
the scaffold protein APAF-1, following its binding to cyto-
chrome-c, oligomerizes. The complex then recruits caspase-9 
that becomes activated [24]. Mitochondrial release of cyto-
chrome-c is mediated by Bax and Bak, the activity of which 
is controlled by the balance of pro- versus anti-apoptotic 
members of the Bcl-2 family [25]. The extrinsic pathway, on 
the other hand, relies on the stimulation of death receptors 
that activate caspase-8 and -10 [14]. The extrinsic pathway 
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has the possibility to cross-talk with the intrinsic pathway by 
inducing the cleavage of Bid, a BH3-only Bcl-2 family 
member [14] (see below). There are additional apoptosis 
regulatory proteins, including the inhibitors of apoptosis pro-
teins (IAP) family [26,27] and proteins like Smac/DIABLO 
that is released from mitochondria together with cytochrome-
c and that prevents IAPs from inhibiting caspases [28]. 
 In pre-malignant cells, apoptosis can be triggered by 
DNA damages resulting from oncogene activation [29]. 
Death receptor ligands can also stimulate tumor cell apopto-
sis, and some of these (e.g. TRAIL) appear to selectively 
target cancer cells and leave normal cells unaffected [30]. As 
indicated above, cancer progression often implies acquired 
resistance to this type of apoptosis and to cell death mediated 
by anti-cancer drugs [31]. Due to the variety of signals that 
lead to apoptosis, it is nevertheless still possible, at least in
vitro, to induce death in cancer cells if the appropriate stim-
uli are used. However, these stimuli might not always be 
compatible with an in vivo usage due to toxicity to normal 
tissues. Restoration of apoptosis sensitivity in tumor cells 
can potentially be achieved by counteracting the action of the 
proteins that inhibit apoptosis and by favoring the activity of 
those that stimulate it. Several synthetic peptides have been 
shown to be able to do so. 
Therapeutic Peptide Design Improvement 
 Many molecules displaying potent effects on tumor cells 
in vitro apparently fail to reach clinical trials because either 
of low delivery efficiency or low bioavailability and in vivo
stability. A potent but non-deliverable drug is useless. A 
major concern in therapeutic development is therefore drug 
delivery. For these reasons, effort has been put into develop-
ing efficient delivery strategies including nano-particle-, 
polycationic- and lipid-based methods [11]. However, only a 
few of them have reached clinical trials [9]. 
 Methods based on cell-penetrating peptides (CPPs) have 
promising potential in the context of drug delivery. They 
have emerged twenty years ago with the discovery of the 
ability of the HIV-1 TAT protein to enter cells [32, 33] and 
the characterization of the TAT sequence allowing this to 
occur [32, 34-36]. Since then, a variety of other CPPs were 
identified, often from natural proteins [37], including pene-
tratin, a 16-mer-peptide derived from the Antennapedia ho-
meodomain-containing protein of Drosophila melanogaster
[38], VP-22, a protein from the herpes simplex virus type 1 
[39], Pep-1, a synthetic peptide derived from the nuclear 
localization sequence of the SV40 large T antigen [40], 
polyarginine sequences [41], and many others (reviewed in 
[37]). Although the mode of cellular entry of CPPs still re-
quires full characterization (reviewed in [37]), their utiliza-
Fig. (1). Apoptotic signaling pathways.The intrinsic and extrinsic pathways are schematized. The main players involved in apoptotic signal-
ing are indicated (see text for details). The anti-apoptotic proteins are grey-colored, while the pro-apoptotic ones are not. 
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tion as cell permeable sequences has been largely adopted. 
Up to now, CPPs have been used as carriers for circular 
DNA, oligonucleotides, siRNA, liposomes, proteins, pep-
tides [37] and even the anti-cancer drug doxorubicin [42]. 
CPPs can be used in vivo to deliver their cargo to virtually all 
tissues [43]. Methodologies based on CPPs are constantly 
being improved as demonstrated by the recent characteriza-
tion of penetration accelerating sequences (PAS) that signifi-
cantly increase the cytosolic release of CPPs taken up by 
cells [44]. 
 One potential problem with peptides is rapid degradation 
in biological fluids. Peptide stability can be greatly amelio-
rated however if they are synthesized using D-amino acid 
enantiomers instead of the natural L-amino forms because D-
amino acid peptides cannot be easily recognized by proteases 
[45]. To best mimic the structure of the natural peptides, the 
sequence of the D-peptide is generally inverted, generating 
the so-called retro-inverso form [45]. 
 Another arm of improvement in anti-cancer drug devel-
opment concerns target specificity. Efforts are therefore 
made to specifically deliver these drugs to cancer cells. This 
could be achieved by taking advantage of the fact that tumor 
cells express proteins that are not present on normal cells (or 
at least not to the same levels). Drugs can be modified so as 
to contain structures allowing them to bind cancer-specific 
proteins or molecules. A list of the most cancer specific pro-
teins has been published [46]. Some of these proteins could 
be targeted for the development of cancer homing devices. 
Examples include the chemokine receptor CXCR4, the lu-
teinizing hormone releasing hormone receptor LHRHR and 
survivin. Another example is the GRP78/BiP endoplasmic 
reticulum chaperone that, in contrast to normal cells, is often 
expressed at the surface of cancer cells [47]. It has been 
shown that GRP78/BiP binding peptides linked to cytotoxic 
peptides specifically target and kill cancer cells in vivo [48], 
providing the proof-of-concept that cell surface GRP78/BiP 
can mediate tumor-specific internalization of cytotoxic com-
pounds. 
PEPTIDES TARGETING MEMBERS OF THE APOP-
TOSIS SIGNALING PATHWAY 
Bcl-2 Family-Derived Peptides 
 The Bcl-2 protein family is a major component in the 
apoptotic signaling pathway, and the improper regulation of 
some of its members is associated with drug resistance and 
malignant diseases [49]. Bcl-2 family proteins contribute to 
cell death via the mitochondrial pathway in response to 
DNA-damage, gamma-irradiation, growth factor deprivation, 
but also after activation of death receptors (e.g. Fas, TNF, 
TRAIL) and cross-talk with the mitochondrial intrinsic 
pathway [50, 51]. Bcl-2-family members are divided in two 
categories bearing opposite activities in the regulation of 
apoptosis. Pro-apoptotic Bcl-2 family members are them-
selves subdivided in two additional groups, those harboring 
three Bcl-2 Homology (BH) domains, including Bax and 
Bak, and those containing only the third BH domain, the so-
called “BH3-only” proteins, including Bid, Bad and PUMA. 
Anti-apoptotic Bcl-2 family proteins, such as Bcl-2 and Bcl-
XL, bear the same three BH domains (BH-1 to -3) as the pro-
apoptotic ones but they also harbor a fourth domain (the 
BH4 domain) implicated in their anti-apoptotic activity [52]. 
However, the mere presence of the BH4 domain does not 
necessarily make its bearer an anti-apoptotic protein as some 
pro-apoptotic Bcl-2- family members, such as Diva and Bcl-
XS, do contain this domain [53, 54]. 
 The balance of pro- and anti-apoptotic proteins tightly 
determines the fate of a cell and Bcl-2 family members play 
a major role in this regulation. In healthy cells, Bcl-2 and 
Bcl-XL bind to Bak and Bax to block their ability to release 
cytochrome-c (Fig. 1). Upon apoptogenic stimuli, BH3-only 
proteins bind to anti-apoptotic Bcl-2 family members, leav-
ing Bax and Bak free to be activated to form the cytochrome-
c releasing structure in the mitochondrial membrane. The 
BH3-only proteins Bid and Bim are not only favoring cell 
death by titrating anti-apoptotic members. They may also 
directly activate Bax and Bak [55]. One model postulates in 
fact that inhibition of anti-apoptotic Bcl-2 family members is 
insufficient to cause apoptosis in the absence of direct Bax 
and Bak activation (i.e. by Bid or Bim) [56]. This model 
appears however incompatible with a number of observa-
tions, including data showing that Bid-/- Bim-/- fibroblasts 
remain sensitive to pro-apoptotic stimuli activating the in-
trinsic death pathway (reviewed in [57]). Recently, however, 
a NMR analysis has revealed a physical interaction site on 
Bax for a Bim-derived synthetic peptide located away from 
the hydrophobic BH3-binding pocket of Bax [58]. This 
newly identified site seems to account for the direct activat-
ing effect of Bim on Bax [58]. 
 Bcl-2 family proteins are deregulated in most cancers and 
they play an important role in cancer chemo-resistance [59, 
60]. Very recently, Bcl-2 has also been shown to be involved 
in cell invasion and metastasis formation [61], making it an 
even more attractive target for cancer therapy. Bcl-2 and 
Bcl-XL are often over-expressed in cancer cells. As a conse-
quence, the activation of Bax and Bak is impaired, prevent-
ing cells from undergoing apoptosis. Thus, agents that are 
able to disrupt the interaction between pro- and anti-
apoptotic Bcl-2 proteins have attractive therapeutic potential. 
The conceptual goal in Bcl-2 family targeting is to mimic the 
pro-apoptotic proteins or to inhibit the anti-apoptotic ones. 
Since Bcl-2 family dimerization is mediated mainly by the 
BH3 domain, most efforts are devoted to synthesize small 
BH3-mimicking molecules or peptides that can inhibit anti-
apoptotic Bcl-2 family members. The laboratory of David 
Huang provided in 2005 a thorough analysis of the affinity 
of eight BH3 peptides for five Bcl-2-like proteins [62]. It 
was found that PUMA and Bim were the only BH3-only 
proteins able to engage all anti-apoptotic Bcl-2 family mem-
bers. Other BH3-only proteins displayed a more limited 
spectrum of interactions. This information can be useful in 
defining the most appropriate BH3 peptides to be used to 
treat cancers over-expressing given pro-survival Bcl-2 fam-
ily members. 
Bak-Derived Peptides 
 Both Bak and Bax are proteins involved in formation of 
cytochrome-c releasing structures in the mitochondrial 
membrane [57]. In a healthy cell, Bak is anchored in the mi-
tochondrial membrane, while Bax is mainly located in the 
cytoplasm. During the apoptosis process, both are localized 
and activated in the mitochondrion membrane, where they 
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exert their permeation function. This leads to the release of 
cytochrome-c from the mitochondria, as well as other pro-
apoptotic effectors including Smac, AIF, endonuclease G 
[63]. As indicated above, Bak and Bax are inhibited when 
they bind to Bcl-2 family members. Preventing such interac-
tions is therefore an attractive way to prompt cancer cells to 
undergo apoptosis. 
 One of the first identified peptide targeting a Bcl-2 fam-
ily member was described in 1997 by the laboratory of Ste-
phen Fesik [64]. It corresponds to a 19 amino acid-long se-
quence derived from the BH3 domain of Bak that binds and 
negatively titrates out Bcl-XL [65]. This peptide was used to 
determine the 3D-structure of the interaction between Bcl-XL
and the death-promoting region of Bak [64]. When coupled 
to the penetratin CPP, this peptide, within 3-6 hours, induces 
cell death with the characteristic morphological features of 
apoptosis such as reduction in cell volume, nuclear conden-
sation and membrane blebbing [64]. A mutant peptide unable 
to bind to Bcl-XL does not induce apoptosis [64]. This indi-
cates that inhibition of Bcl-XL, and possibly other anti-
apoptotic Bcl-2 family members, mediates the apoptotic re-
sponse induced by the Bak-BH3 peptide. 
 A major concern in cancer therapy is to minimize the side 
effects of drugs on normal tissues. In this context, targeting 
drugs directly to cancer cells would be beneficial. Dharap et
al. took advantage of the fact that luteinizing hormone-
releasing hormone (LHRH) receptors are expressed at the 
surface of ovarian, breast and prostate cancer cells but not in 
most other visceral organs. They coupled a Bak-derived BH3 
peptide to a decapeptide from LHRH and found that this 
hybrid peptide was able to kill specifically LHRH receptor-
expressing cells [66]. Such an approach represents an elegant 
solution to deliver anti-cancer peptides to their targets and 
spare bystander cells. It has been shown indeed that the 
LHRH decapeptide allows the genotoxin drug camptothecin 
to induce a stronger and more specific anti-tumoral effect in
vivo [67]. One can therefore predict that hybrid peptides 
composed of BH3 sequences and the LHRH decapeptide will 
also be more efficacious in whole organisms compared to 
peptides lacking the tumor-homing device. 
 Head and neck squamous cell carcinoma (HNSCC) can 
be treated by gamma radiation, EGF receptor inhibition, and 
chemotherapy after surgery [68], but unfortunately these 
treatments, if not fully efficacious, often select tumor cells 
with increased resistance to therapy [69]. These resistances 
can theoretically result from Bcl-2 and Bcl-XL overexpres-
sion that would prevent Bak and Bax activation [70]. Li et al.
used a 19-mer Bak-derived peptide fused to penetratin or 
polyarginine CPPs in order to buffer the anti-apoptotic activ-
ity of Bcl-2 and Bcl-XL in three HNSCC cell lines and this 
led to efficient killing of the tumor cells [71]. 
Bax-Derived Peptides 
 An early study on the Bcl-2 family interactions [72] re-
ported that mutations within the BH1 and BH2 domains of 
Bcl-2 abrogate the Bcl-2-Bax heterodimerization while not 
affecting the Bcl-2-Bcl-2 homodimerization, suggesting that 
Bcl-2 binding sites for Bax and Bcl-2 itself were not identi-
cal. Three years later however, evidence was presented that 
only one site was responsible for these bindings, including 
the description of a 15-mer Bax peptide (Bax amino acids 
59-72) able to block Bcl-2 and Bcl-XL homodimerization 
and Bax binding to either Bcl-2 or Bcl-XL [73]. Regardless 
of whether the binding of Bax to Bcl-2 involves the same 
region necessary for Bcl-2 dimerization, the identification of 
a Bax-derived peptide able to disrupt complexes between 
pro- and anti-apoptotic Bcl-2 family members opened the 
possibility to use it as a tool to promote cancer cell death. 
Bax (and Bak) BH3-derived peptides were indeed shown to 
induce cytochrome-c release from isolated mitochondria [74] 
indicating that disruption of pro- and anti-apoptotic Bcl-2 
protein complexes leads to a functional activation of the in-
trinsic apoptotic pathway. The pro-apoptotic activity of Bax 
peptides was then shown on whole cells after electroporation 
[75], microinjection in cells [76], or using cell-permeable 
version of the peptide [71,77]. Induction of apoptosis by the 
Bax BH3 peptide appears to occur through disruption of the 
pro-and anti-apoptotic Bcl-2 protein complexes rather than 
by direct activation of Bak and Bax as the peptide is neither 
able to induce Bax translocation to the mitochondria nor to 
stimulate the apoptotic activity of a recombinant form of Bax 
[78]. 
 Calpain is a calcium-dependant protease that can cleave 
Bax into a 18 kDa fragment (p18Bax) and a 32 amino acid 
peptide (p3Bax) [79] (Fig. 1). The consequence of this 
cleavage is that it generates a more active version of Bax 
(p18Bax) [80]. The function of p3Bax is less well under-
stood. A cell-permeable version of p3Bax (TAT-p3Bax) 
slightly enhances apoptosis in response to the Sarco/ Endo-
plasmic Reticulum Ca2+-ATPase (SERCA) inhibitor thapsi-
gargin by increasing the release of calcium into the cyto-
plasm. Although it has been suggested that this release in-
volves the inositol 1,4,5-triphosphate receptor (IP3R), the 
underlying mechanisms remain at the moment elusive [81]. 
TAT-p3Bax alone does however not affect cell survival. 
Prostate and colon cancer cells display increased expression 
of transient receptor potential cation channel subfamily M 
member 8 (TRPM8), a plasma membrane Ca2+ channel, and 
decreased SERCA3 levels, respectively (reviewed in [82]). 
This would favor elevation in cytosolic Ca2+. If TAT-p3Bax 
favors apoptosis in cells with increased cytosolic calcium 
concentrations it could then potentially be efficacious in 
treating these cancers. 
PUMA-Derived Peptides or Peptides Favoring the Activity 
of PUMA 
 p53-upregulated modulator of apoptosis (PUMA) is a 
pro-apoptotic BH3-only protein, the expression of which, as 
its name implies, is controlled by p53 [83]. It binds and in-
hibits all known anti-apoptotic Bcl-2-family members [62] 
and may be able, although this is debated, to directly activate 
Bax and Bak [57]. PUMA mediates apoptosis of cells in re-
sponse to stresses such as DNA damage that lead to p53 ac-
tivation but also in response to p53-independent apoptotic 
stimuli (e.g. staurosporine) [84, 85]. 
 It has recently been reported that a cell-permeable 
PUMA-derived peptide can trigger apoptosis in a broad 
panel of cancer cell lines, but not normal cells [86]. This 
peptide is composed of a 9 amino acid sequence found in the 
BH3 domain of PUMA (LRRMADDLN) that has the capac-
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ity to dissociate Bcl-XL from Bax [87]. It also contains the 
sequence encoding the CXC chemokine receptor-4 (CXCR4) 
ligand allowing it to bind to this receptor. As many tumors 
from different origins over-express this receptor [88], this 
might allow preferential targeting of the PUMA-containing 
pro-apoptotic peptide to its intended target. Consistent with 
this prediction is the observation that injection of this peptide 
in the tail vein preferentially accumulated in tumors in mice 
[86]. Future in vivo investigations will tell whether this en-
hanced targeting to tumors correlates with a better anti-tumor 
activity compared to peptides lacking the CXCR4 receptor 
ligand sequences. 
 Our laboratory has characterized a peptide that is not 
derived from a Bcl-2 family member but that nevertheless 
impinges on the p53-PUMA pathway to favor the death of 
cancer cells. This peptide is derived from a caspase-3-
generated fragment of the RasGAP protein, called fragment 
N2, that specifically sensitizes tumor cells to genotoxin-
induced apoptosis [89]. Fragment N2 renders tumor cells 
such as HeLa, U2OS, and HCT116 cells exquisitely sensitive 
to the killing action of various genotoxins (cisplatin, 
adriamycin, mitoxantrone, etc) [90, 91]. The genotoxin-
sensitizing activity of fragment N2 has been narrowed down 
to a 10 amino acid long sequence [89]. TAT-RasGAP317-326,
a synthetic, cell-permeable peptide bearing this sequence, 
increases the ability of genotoxins to induce apoptosis in 
tumor cells [89]. Recently, a more stable version of the pep-
tide, made of D-amino acids, has been demonstrated to in-
crease the efficacy of genotoxins in several tumor mouse 
models [92]. This peptide only functions in cells expressing 
a functional p53 protein and its genotoxin-sensitization activ-
ity requires PUMA [93]. As TAT-RasGAP317-326 does not 
modulate the activity of p53 or the levels of PUMA, our cur-
rent working hypothesis is that it increases the activity of 
PUMA, consistent with the observation that the extent of 
mitochondrial potential decrease induced by cisplatin is 
augmented in presence of the peptide [93]. 
Bad-Derived Peptides 
 Bad is another BH3-only protein that binds to Bcl-2, Bcl-
XL, and Bcl-w [62, 94]. There are indications that the Bad 
BH3 domain has higher binding affinities for Bcl-XL than 
BH3 domains from other Bcl-2 family members [95]. Bad-
derived peptides may therefore represent particularly potent 
anti-cancer tools to treat cancer cells with increased expres-
sion of Bcl-XL. The first design of a cell-permeable Bad-
derived peptide to treat tumor cells was reported in 2000 
[96]. This peptide, called cell permeable moiety (cpm)-1285 
corresponds to a 24 amino acid-long sequence derived from 
the Bad BH3 domain (amino acid 142–165) coupled to a 
decanoid fatty acid [CH3(CH2)8CO] to render it cell perme-
able. Cpm-1285 binds strongly to Bcl-2 with an IC50 of 130 
nM, while a mutated peptide, in which the Bad BH3 leucine 
151 is mutated into an alanine, has 15 times increased IC50.
Cpm-1285 was shown to induce apoptosis of HL-60 cells, a 
human myeloid leukemia cell line. The caspase inhibitor z-
VAD-fmk could block this response, strengthening the no-
tion that the peptide was mediating its effects through 
caspase activation. A non-cancerous peripheral blood lym-
phocyte (PBL) cell line was not affected by the presence of 
the peptide, emphasizing its cancer specificity. SCID mice 
injected with HL-60 tumor cells subsequently treated with 
the mutant peptide or left untreated survived approximately 
11-12 days, while mice treated with cpm-1285 had their 
lifespan extended by 27 days. This promising leukaemia 
therapy strategy now needs to be translated to human. 
 One year later, in 2001, another Bad peptide (amino acid 
103 to 123), encoding the -helical structure of the BH3 
domain, was coupled to the penetratin CPP and tested for its 
ability to kill cells [97]. This peptide, called ANTBH3BAD, 
efficiently interacted with Bcl-2. Surprisingly however, it 
induced apoptosis in a Bcl-2-independent manner and it was 
found that its toxicity was actually due to its alpha helicity. 
Alpha-helical structures when amphipathic and when bearing 
cationic residues are known to break the positively charged 
membrane of bacteria, but not those of mammalian cells that 
are neutrally charged and stabilized by cholesterol [98, 99]. 
When such peptides are internalized into mammalian cells 
however, they are able to disrupt the negatively charged mi-
tochondrial membrane and this leads to the activation of the 
apoptotic intrinsic pathway [100]. Thus, the ANTBH3BAD 
peptide appears to induce cell death like cationic amphipa-
thic helices and will therefore not be able to discriminate 
between normal and cancer cells, unless modified in such a 
way as to specifically target the latter. 
 Since interaction of Bcl-2 family members is mediated 
by their BH3 domains, the specificity and strength of these 
interactions are important parameters to gather in order to 
define which BH3 peptide-based strategies have to be 
elected according to the Bcl-2 protein expression profile of 
the cancers to be treated. A study published in 2002 provided 
some information in this context [101]. Comparison of the 
efficacy of BH3 peptides derived from Bax, Bad and Bcl-2 
for their ability to disrupt Bax/Bcl-2 and Bax/Bcl-XL het-
erodimers and Bax or Bcl-2 homodimers indicated that the 
Bax peptide is more potent in dissociating Bax/Bcl-2 com-
plexes, while the Bad peptide is more efficacious in disrupt-
ing Bax/Bcl-XL complexes. These in vitro results suggest 
that Bax peptides should be used to treat cancer over-
expressing Bcl-2, while Bad peptides should be chosen to 
treat those that over-express Bcl-XL. However, care must be 
taken here because works with cancer cells do not always 
confirm such assumption (see [71] for example). Obviously, 
the situation with living cells is more complex and additional 
cell death regulators will determine the eventual efficacy of a 
given BH3-derived peptide on tumors. 
Bid-Derived Peptide 
 Bid is a peculiar BH3-only protein because it can link the 
extrinsic and the intrinsic pathways when it is cleaved by 
caspase-8 [14]. It mediates its pro-apoptotic activity by inter-
acting with the anti-apoptotic Bcl-2 members and maybe 
also by directly activating Bax and Bak [55]. The group of 
Stanley Korsmeyer modified BH3 -helical structures using 
a method termed hydrocarbon stapling that consists in re-
placing the amino-acids on one side of the helix with non-
natural chemically modified amino-acid that covalently in-
teract, thereby stabilizing the helix chemical structure and 
increasing its in vivo activity. The resulting peptides were 
called “stabilized -helix of Bcl-2 domains” (or SAHBs) 
[102]. A SAHB of the BH3 domain from the Bid protein 
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(amino acid 80 to 101) displayed stronger apoptotic-inducing 
activities compared to the non-modified Bid peptide. Addi-
tionally, the Bid SAHB effectively inhibited the growth of 
human leukemia xenografts in mice. SAHBs therefore repre-
sent potentially useful tools to treat cancer with deregulated 
Bcl-2 proteins. 
Bim-Derived Peptides 
 Bim is a BH3-only Bcl-2 family member, the activity of 
which is controlled through its interaction with microtubule 
structures. Bim is inactive when bound to microtubule-
associated dynein motor complexes but its release from it, in 
response to microtubule perturbing drugs for example, al-
lows it to inhibit anti-apoptotic Bcl-2 proteins, favoring 
therefore apoptosis. Bim, and another BH3-only member 
called Bmf that interacts with actin structures, allow there-
fore cells to engage an apoptotic program when their cy-
toskeleton is damaged. Bim can also be regulated by ERK-
mediated phosphorylation [25]. As indicated above, Bim, 
like PUMA, has the capacity to titrate all pro-survival Bcl-2 
proteins and consequently use of Bim mimetics can poten-
tially have great efficacy in killing cancer cells. 
 As can be expected from its mode of activation, Bim 
plays an important role in taxane-induced cancer cell apopto-
sis. Taxanes (e.g. taxol, paclitaxel) stabilize microtubules, in 
particular those of the spindle apparatus, and this induces 
cell cycle arrest at the G2/M stage, spindle check-point acti-
vation, and subsequently apoptosis [103]. Taxanes are effec-
tive chemotherapeutic agents against cancers originating 
from lung, prostate and breast. The susceptibility of cancer 
cells to taxane-induced apoptosis has been shown to depend 
on the levels of Bim expression [104]. Taxanes might not 
only liberate pools of Bim initially associated with microtu-
bule structures, they also appear to induce de novo expres-
sion of Bim [104,105], via Foxo3a-mediated transcription 
[105]. 
 A peptide containing the cell permeable TAT moiety and 
sequences from the BH3 domain of Bim has been used to 
successfully kill various cancer cells in vitro [106]. Intra-
tumoral injection of this peptide was also able to slow down 
the growth of a pancreas adenocarcinoma tumor implanted in 
syngeneic mice and to increase the survival of these animals 
[106]. It will now be interesting to see if stabilized version of 
Bim peptides, such as those used in the characterization of 
the Bim binding site on Bax [58], are efficacious in vivo anti-
tumor agents. It has to be kept in mind however that Bim is 
able to inhibit all pro-survival Bcl-2 proteins and this might 
lead to unacceptable side-effects on normal tissues.  
Bcl-2 and Bcl-XL BH4-Based Peptides 
 The anti-apoptotic Bcl-2 and Bcl-XL proteins are up-
regulated in several common human malignancies, including 
prostate, colon, breast, small cell lung cancer, and follicular 
B-cell lymphoma, and this correlates with poor prognosis 
and chemotherapy resistance [50, 107]. Since BH4, a domain 
borne by both Bcl-2 and Bcl-XL, is essential for their anti-
apoptotic effect on pro-apoptotic Bcl-2 family members 
[108], it is of particular interest for drug designers. 
 Another interesting aspect of the BH4 domain is that it 
appears to negatively regulate calcium-dependent apoptosis. 
The BH4 domain interacts with the IP3R, inhibiting the IP3-
mediated Ca2+ release from the endoplasmic reticulum to the 
cytoplasm and, this consequently can prevent Ca2+-induced 
apoptosis [52, 109]. A peptide-based approach preventing 
the BH4-IP3R interaction has been designed to prevent this 
inhibitory action of the BH4 domain (reviewed in [110]). 
The laboratory of Clark Distelhorst identified a 20 amino 
acids sequence within the IP3R, which they called “peptide 
2”, that was shown to mediate the binding of the IP3R to the 
Bcl-2 BH4 domain [111]. As expected, this peptide was able 
to abrogate the IP3R-Bcl-2 interaction, thereby reversing the 
Bcl-2 inhibitory effect on IP3R channel opening. The anti-
cancer activity of this peptide has yet to be evaluated. 
IAPs and Smac-Derived Peptides 
 A cell that needs to survive has to tightly control its 
caspase activity. Inhibitors of apoptosis proteins (IAPs) rep-
resent one family of proteins that can be used by cells to 
achieve this regulation. IAPs inhibit caspases either directly 
by binding to them or indirectly by promoting their degrada-
tion [112]. The best described IAP members are XIAP, c-
IAP1, c-IAP2, and survivin. IAP over-expression, survivin in 
particular, is one of the reasons cancer cells develop resis-
tance against chemotherapy [26]. IAP family members share 
four domains: the baculoviral IAP repeat (BIR) domain, the 
caspase recruitment domain (CARD), the really interesting 
new gene (RING) and the ubiquitin-conjugated (UBC) do-
mains. IAPs can contain up to three BIR tandem repeats, 
called BIR1, BIR2, and BIR3. Only CARD and BIR do-
mains are involved in the inhibition of caspases. 
 Second mitochondria-derived activator of caspase/direct 
inhibitor of apoptosis-binding protein with low pI 
(Smac/Diablo) is a protein that homo-dimerizes [113] and 
that is released from mitochondria in response to apoptotic 
stimuli [28]. In the cytoplasm, Smac inhibits IAPs by bind-
ing to their BIR domains. For example, Smac dimers need to 
interact with both the BIR2 and BIR3 domains to be able to 
inhibit XIAP [114,115]. Binding of Smac to IAPs relieves 
the inhibitory action of IAPs on caspases that are then more 
easily activated. Smac may also directly activate caspase-3, 
at least in vitro [113]. Strategies to induce apoptosis in can-
cer cells are often based on peptides mimicking the IAP-
binding motif of proteins with the expectation that such pep-
tides would prevent IAPs from interacting and inhibiting 
caspases. 
Smac-Derived Peptides 
 The majority of the peptides designed to inhibit IAPs are 
based on Smac-derived peptides. The group of Yigong Shi 
defined that the four first amino acids of the N-terminus of 
Smac (AVPI) are responsible for the binding to the BIR3 
domain of XIAP [116]. This knowledge was used to create a 
cell-permeable peptide composed of the TAT CPP linked to 
the seven first amino acids of Smac [117]. The resulting pep-
tide was able to sensitize neuroblastoma cells, and other can-
cer cell lines, towards TRAIL-, CD95- and chemotherapy 
induced apoptosis. Three other malignant glioma cell lines 
were sensitized against doxorubicin, cisplatin and etoposide. 
Interestingly, four non-malignant human cell lines were not 
responsive to the peptide, highlighting the cancer-specificity 
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of this approach. A complete eradication of pre-established 
gliomas was found in mice that were treated with the combi-
nation of TRAIL and the Smac peptide, while only a de-
crease in tumor volume was found when each treatment were 
performed independently.  
 Other ensuing studies showed that Smac peptides linked 
to other CPPs, like penetratin or polyarginine, mediated or 
sensitized cell death in different cancer-type contexts, in-
cluding breast cancer [118], lymphoma [119], glioblastoma 
[120] and non-small cell lung cancer [121]. Most of these 
peptidic versions were shown to restore the sensitivity of 
cancer cells to different chemotherapies by removing the 
inhibitory effect of IAPs (such as XIAP, cIAP-1 and cIAP-2) 
on caspase-3, 7 and 9. 
 The first four amino acids of Smac are crucially required 
for its binding to XIAP [116]. The fourth amino acid in this 
sequence is however the least sterically hindered [116]. 
Modification of this sequence to improve the binding of 
Smac to its effectors was therefore thought best attempted at 
this position. Indeed, conversion of the fourth isoleucine into 
phenylalanine resulted in a great improvement of Smac bind-
ing to XIAP [122]. As Smac functions as a dimer, it was 
hypothesized that bivalent Smac-derived peptides would be 
more efficacious. Using the phenylalanine-modified version 
of the Smac N-terminal tetrapeptide, a dimer linked by the 
flexible adipic acid was generated and found to be 10’000 
fold more potent than the monomer version in binding to the 
BIR2 and BIR3 of XIAP [123]. Cell-permeable versions of 
this bivalent Smac peptide will hopefully be developed soon 
to determine their functional efficacy as apoptosis-promoting 
tools in cancer cells. 
 Most studies about inhibition of IAPs are focusing on 
XIAP because it has a wide and ubiquitous expression and 
because it is the most potent and versatile member of its fam-
ily [112]. However, other IAPs, such as ML-IAP, have also 
been studied to determine if they could be inhibited by pep-
tide-based constructs. ML-IAP, also known as livin or KIAP, 
bears only one BIR domain (BIR2) that interacts with 
caspase-3, 7 and 9. It is widely expressed in melanoma cell 
lines but not in most normal tissues [124, 125]. This expres-
sion pattern makes ML-IAP an interesting target for the de-
velopment of anti-melanoma drugs. In this context, work has 
been performed to improve the binding and specificity of 
Smac-derived peptides towards ML-IAP [126]. Promisingly, 
modifications of selected residues in the Smac N-terminal 
sequence resulted in a peptide that displayed a 100 times 
greater specificity for ML-IAP-BIR relative to XIAP-BIR3 
[126]. 
Survivin-Derived Peptides 
 Survivin is one of the most interesting IAP members in 
the context of cancer therapy because, in contrast to many 
IAPs, it is generally not expressed in adult tissues but very 
often over-expressed in tumors [127]. A transcriptomic 
analysis singled out survivin as the fourth “most cancer-
specific of all gene products” [46]. Survivin confers apopto-
sis protection by antagonizing caspases. It does so mainly by 
cooperating with other proteins such as HBXIP to inhibit 
caspase-9, by favoring the stability of XIAP, or by compet-
ing with Smac [128]. Additionally, survivin has functions 
distinct from regulation of apoptosis by playing very impor-
tant roles during cell division [127, 128]. The implication of 
survivin in both the control of cell division and the survival 
of cells makes it a prime target for the development of anti-
cancer strategies. 
 The interaction with the HSP90 chaperone is essential for 
survivin stability. An amino acid stretch within the BIR sur-
vivin is required for this interaction to occur [129]. The labo-
ratory of Dario Altieri used the minimal number of amino 
acids required for survivin binding to HSP90 (K79-L87), 
which they called “shepherdin”, to down-regulate survivin 
levels in cells [130]. They produced a cell-permeable peptide 
encoding the K79-L87 sequence and found that it selectively 
killed tumor, but not normal, cells [130]. The ability of shep-
herdin to kill cells was p53-independent, an important prop-
erty in the context of cancer therapy as most tumor cells have 
lost a functional p53 pathway. Interestingly, shepherdin also 
prevented HSP90 from binding to and stabilizing other of its 
client proteins, including well-known pro-cancer proteins 
such as Akt [130]. In addition, in vivo experiments validated 
the efficacy of a retro-inverso version of shepherdin in im-
munocompromised mice bearing xenograft tumors, as well 
as in a mammary cancer mouse model [130]. The broad 
spectrum of cancer cell types targeted by shepherdin coupled 
to its apparent lack of adverse effect on normal tissues makes 
this peptide one of the most promising anti-tumor peptide-
based candidates currently available. As survivin plays a 
crucial role during cell division, the impact of shepherdin on 
organs that display high tissue renewing, such as the intes-
tine, will have to be monitored very closely though. 
p53-Derived Peptides 
 p53 is one of the best known tumor suppressors [131]. It 
is a stress and oncogenic sensor able to either inhibit cell 
cycle for repair or induce apoptosis [131]. The ability of p53 
to counteract cancer development is best correlated with its 
apoptosis-inducing capacity [132]. Unsurprisingly, p53, and 
p53 regulators, are mutated in many human cancers so as to 
render the p53 pathway ineffective [131,132]. This correlates 
with poor prognosis [133]. Restoration of a functional p53 
apoptosis signaling response in cancer cells represents there-
fore an attractive approach to fight cancer development. In a 
pioneer work [134], David Lane and colleagues synthesized 
a 15 amino acid long peptide derived from a carboxy-
terminal domain of p53 that negatively regulates its own 
transcriptional activity and showed that this peptide can acti-
vate latent forms of p53 when injected into cells. The peptide 
was thus relieving the auto-inhibitory function of the C-
terminal sequences of p53. Importantly in the context of can-
cer therapy, the peptide was able to activate several p53 mu-
tants [135] and induce the death of the cells expressing those 
mutants [136]. Despite its ability to activate wild-type p53, 
the C-terminal p53 peptide does not induce apoptosis in pri-
mary cells [136] presumably because of low p53 expression 
and absence of oncogenic apoptosis-prone signals in normal 
cells. Based on these earlier findings, the laboratory of Ste-
ven Dowdy developed a retro-inverso cell-permeable version 
of the p53 peptide by coupling it to the HIV-TAT CPP. The 
resulting peptide, called RI-TATp53C’, when injected into 
mice, inhibited the growth of sub-cutaneous tumors, perito-
neal carcinomas and lymphomas [137]. To assess whether 
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the RI-TATp53C’ could be modified so as to target cancer 
cells more specifically, the same laboratory hooked to the 
peptide the DV3 domain from the CXC chemokine receptor-
4 (CXCR4) ligand [138]. The CXCR4 ligand appears par-
ticularly suited here because it is small, its receptor CXCR4 
is over-expressed on many tumor cell types, and importantly 
its synthesis using D-amino acids does not adversely affect 
its ability to bind CXCR4 [139]. Compared to the unmodi-
fied RI-TATp53C’ peptide, the DV3-RI-TATp53C’ peptide 
in vitro had a stronger apoptotic activity in CXCR4-
expressing tumors. Both peptides had similar killing activi-
ties in non-CXCR4-expressing tumor cells [138]. It will now 
have to be determined if the DV3-RI-TATp53C’ peptide has 
increased CXCR4-specific anti-tumor activity in vivo.
 Recently, the group of Giannino Del Sal created a series 
of mutant p53-targeting peptide aptamers [140]. Aptamers 
consist of short variable peptides expressed on a constant 
presenting structure that are generated in combinatorial li-
braries and that can be used to select sequences able to bind 
to proteins or structures of interest [141]. The identified ap-
tamers were able to induce apoptosis in mutant p53-
expressing tumor cells but they had no effect on cancer cells 
lacking p53 or expressing wild-type p53 [140]. However, 
these aptamers did not reactivate the wild-type functions of 
p53 (e.g. induction of p21 transcription). How they induce 
death in p53 mutant expressing cells remain therefore to be 
determined. 
Natural Peptides 
 The discovery of taxol as a potent anti-cancerous com-
pound [142] is an emblematic example of the usefulness of 
natural product drug discovery programs (and a reminder of 
the importance of preserving bio-diversity on our planet). 
And indeed, a series of natural peptides have been identified 
as potential anti-cancer compounds. The following is a non 
exhaustive list of examples. Cecropins (CB) are antimicro-
bial 34- to 39-mer peptides found in the hemolymph of the 
Cecropia moth (Hyalophora cecropia), the largest North 
American moth. Some of them were shown to kill HL-60 
leukemia cells with minimal effects on non-tumoral 3T3 
fibroblasts [143]. Magainins are a class of peptides isolated 
from Xenopus laevis skin that are able to form pores and 
thereby lyse hematopoietic tumors with a relatively low cy-
totoxicity against differentiated tissues [144]. Melittin, a 26 
amino acid-long peptide isolated from the bee venom, ap-
pears to preferentially kill cancer cells over-expressing Ras 
[145]. Additional anti-cancer peptides have been isolated 
from very varied sources, including rapeseed (Brassica 
napus) [146], soy (Glycine max) [147], the grouper Epi-
nephelus coioides [148], the marine mollusc Dolabella 
auricularia [149], and even humans [150]. The anti-tumoral 
properties of natural peptides may not be potent and selective 
enough to allow these compounds to be used as is in humans. 
They however offer the base for further development and 
modifications to increase their efficacy as anti-cancer com-
pounds, as shown recently for cecropins [151]. 
CONCLUSION 
 This review was aiming at showing the breadth of anti-
cancer peptide research. The majority of the peptides dis-
cussed here display important anti-cancer activities in vitro,
and many were tested and validated in vivo for their effect on 
tumor development. Some anti-cancer peptides are now used 
in clinical studies [9]. However, none so far have the ability 
to home specifically to their targets, even though many in-
duce a stronger death response in tumor cells than in normal 
tissues. It may therefore be very valuable to modify anti-
tumor peptides so that they only target cancer cells. As indi-
cated in this review, a vast number of apoptosis-inducing or 
apoptosis-sensitizing peptides already exist. Moreover, the 
targeting methods and the mode of peptide delivery in vivo
are constantly being improved. One of the next challenges in 
this field will be to determine the best match between the 
peptide bearing the anti-cancer activity and the chemical 
modifications or additions that will help the peptide dis-
criminate better between normal and tumor cells. Another 
research axis will be to determine whether combinations of 
anti-cancer peptides and drugs currently used in the clinic to 
treat cancers display synergistic therapeutic efficacy. Hope-
fully, this research will soon lead to the development of anti-
tumor therapeutical peptides that will be efficacious in treat-
ing cancer patients. 
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